644 related articles for article (PubMed ID: 29584848)
1. HIV Preexposure Prophylaxis: A Review.
Riddell J; Amico KR; Mayer KH
JAMA; 2018 Mar; 319(12):1261-1268. PubMed ID: 29584848
[TBL] [Abstract][Full Text] [Related]
2. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
3. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
[TBL] [Abstract][Full Text] [Related]
4. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
Tang EC; Vittinghoff E; Anderson PL; Cohen SE; Doblecki-Lewis S; Bacon O; Coleman ME; Buchbinder SP; Chege W; Kolber MA; Elion R; Shlipak M; Liu AY
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):193-198. PubMed ID: 28991887
[TBL] [Abstract][Full Text] [Related]
5. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Curry SJ; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Jun; 321(22):2203-2213. PubMed ID: 31184747
[TBL] [Abstract][Full Text] [Related]
6. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
Marrazzo J; Tao L; Becker M; Leech AA; Taylor AW; Ussery F; Kiragu M; Reza-Paul S; Myers J; Bekker LG; Yang J; Carter C; de Boer M; Das M; Baeten JM; Celum C
JAMA; 2024 Mar; 331(11):930-937. PubMed ID: 38427359
[TBL] [Abstract][Full Text] [Related]
7. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
[TBL] [Abstract][Full Text] [Related]
8. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Krakower DS; Mayer KH
Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Okwundu CI; Uthman OA; Okoromah CA
Cochrane Database Syst Rev; 2012 Jul; (7):CD007189. PubMed ID: 22786505
[TBL] [Abstract][Full Text] [Related]
10. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
12. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
Plosker GL
Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
[TBL] [Abstract][Full Text] [Related]
13. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
[TBL] [Abstract][Full Text] [Related]
14. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Chou R; Spencer H; Bougatsos C; Blazina I; Ahmed A; Selph S
JAMA; 2023 Aug; 330(8):746-763. PubMed ID: 37606667
[TBL] [Abstract][Full Text] [Related]
15. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
[TBL] [Abstract][Full Text] [Related]
16. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
D'Angelo AB; Westmoreland DA; Carneiro PB; Johnson J; Grov C
AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141
[TBL] [Abstract][Full Text] [Related]
17. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
Mugwanya KK; Baeten JM
Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
[TBL] [Abstract][Full Text] [Related]
18. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
Molina JM; Capitant C; Spire B; Pialoux G; Cotte L; Charreau I; Tremblay C; Le Gall JM; Cua E; Pasquet A; Raffi F; Pintado C; Chidiac C; Chas J; Charbonneau P; Delaugerre C; Suzan-Monti M; Loze B; Fonsart J; Peytavin G; Cheret A; Timsit J; Girard G; Lorente N; Préau M; Rooney JF; Wainberg MA; Thompson D; Rozenbaum W; Doré V; Marchand L; Simon MC; Etien N; Aboulker JP; Meyer L; Delfraissy JF;
N Engl J Med; 2015 Dec; 373(23):2237-46. PubMed ID: 26624850
[TBL] [Abstract][Full Text] [Related]
19. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.
Petruccelli KCS; Baía-da-Silva DC; Val F; Valões MS; Cubas-Vega N; Silva-Neto AV; Sampaio V; Alencar A; Pecoits-Filho R; Moreira RC; Cardoso SW; Moreira RI; Leite IC; Madruga JV; Kallas EG; Alencastro PR; Hoagland B; Grinsztejn B; Santos VGV; Lacerda MVG
AIDS Res Ther; 2022 Feb; 19(1):12. PubMed ID: 35209929
[TBL] [Abstract][Full Text] [Related]
20. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
Li J; Dufrene SL; Okulicz JF
Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
